Biodel Inc. (Biodel) is a development-stage company. The Company is a specialty biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. The Company’s initial development efforts are focused on peptide hormones. The Company’s product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. In addition to VIAject, the Company is developing VIAtab, a sublingual or below the tongue tablet formulation of insulin. The Company develops its product candidates utilizing its proprietary VIAdel technology, which allows it to study the interaction between peptide hormones and small molecules.